As a proof of concept, we confirmed the clinical significance and prognostic value of two of the eight shortlisted genes (NR2E1, FZD9) belonging to this gene signature in our patient cohort consisting of 80 breast cancer patients. This evidence concerns the gene NR2E1 and breast carcinoma.